$6.37 Billion is the total value of Avoro Capital Advisors LLC's 52 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was 37.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| HZNP | HORIZON THERAPEUTICS PLC | $985,860,000 | +17.0% | 9,000,000 | 0.0% | 15.49% | +5.6% | |
| MRTX | MIRATI THERAPEUTICS INC | $884,550,000 | +9.5% | 5,000,000 | 0.0% | 13.90% | -1.1% | |
| XLRN | Buy | ACCELERON PHARMA INC | $688,400,000 | +82.9% | 4,000,000 | +33.3% | 10.81% | +65.1% |
| UTHR | UNITED THERAPEUTICS CORP | $553,740,000 | +2.9% | 3,000,000 | 0.0% | 8.70% | -7.1% | |
| ASND | Buy | ASCENDIS PHARMAsponsored adr | $315,592,000 | +26.3% | 1,980,000 | +4.2% | 4.96% | +14.0% |
| ARGX | ARGENX SEsponsored adr | $285,843,000 | +0.3% | 946,500 | 0.0% | 4.49% | -9.4% | |
| SRPT | Buy | SAREPTA THERAPEUTICS INC | $231,200,000 | +23.9% | 2,500,000 | +4.2% | 3.63% | +11.9% |
| IOVA | Sell | IOVANCE BIOTHERAPEUTICS INC | $209,610,000 | -11.5% | 8,500,000 | -6.6% | 3.29% | -20.1% |
| ARNA | Sell | ARENA PHARMACEUTICALS INC | $203,959,000 | -26.6% | 3,425,000 | -16.0% | 3.20% | -33.7% |
| FOLD | Buy | AMICUS THERAPEUTICS INC | $168,837,000 | +40.7% | 17,679,273 | +42.0% | 2.65% | +27.0% |
| APLS | Buy | APELLIS PHARMACEUTICALS INC | $164,800,000 | +159.4% | 5,000,000 | +397.4% | 2.59% | +134.3% |
| ALNY | Sell | ALNYLAM PHARMACEUTICALS INC | $160,489,000 | -5.3% | 850,000 | -15.0% | 2.52% | -14.5% |
| BMRN | Buy | BIOMARIN PHARMACEUTICAL INC | $144,919,000 | +5.3% | 1,875,000 | +13.6% | 2.28% | -5.0% |
| VRTX | Sell | VERTEX PHARMACEUTICALS INC | $120,443,000 | -24.4% | 664,000 | -15.9% | 1.89% | -31.7% |
| ISEE | Buy | IVERIC BIO INC | $115,304,000 | +184.4% | 7,100,000 | +10.5% | 1.81% | +156.9% |
| MDGL | MADRIGAL PHARMACEUTICALS INC | $113,701,000 | -18.1% | 1,425,000 | 0.0% | 1.79% | -26.0% | |
| TRILLIUM THERAPEUTICS INC | $100,092,000 | +81.0% | 5,700,000 | 0.0% | 1.57% | +63.4% | ||
| PMVP | Buy | PMV PHARMACEUTICALS INC | $87,165,000 | +39.8% | 2,925,000 | +60.3% | 1.37% | +26.3% |
| KURA | Sell | KURA ONCOLOGY INC | $74,920,000 | -13.2% | 4,000,000 | -3.4% | 1.18% | -21.6% |
| MRSN | MERSANA THERAPEUTICS INC | $64,124,000 | -30.6% | 6,800,000 | 0.0% | 1.01% | -37.3% | |
| GLUE | MONTE ROSA THERAPEUTICS INC | $61,003,000 | -1.9% | 3,311,434 | 0.0% | 0.96% | -11.4% | |
| XENE | XENON PHARMACEUTICALS INC | $55,772,000 | -17.9% | 3,650,000 | 0.0% | 0.88% | -25.9% | |
| New | AADI BIOSCIENCES INC | $53,730,000 | – | 1,829,402 | +100.0% | 0.84% | – | |
| MNKD | Buy | MANNKIND CORP | $38,280,000 | -18.6% | 8,800,000 | +2.0% | 0.60% | -26.5% |
| CBAY | CYMABAY THERAPEUTICS INC | $37,595,000 | -16.3% | 10,300,000 | 0.0% | 0.59% | -24.3% | |
| MARINUS PHARMACEUTICALS INC | $36,814,000 | -36.6% | 3,235,000 | 0.0% | 0.58% | -42.8% | ||
| ACAD | Sell | ACADIA PHARMACEUTICALS INC | $36,542,000 | -38.6% | 2,200,000 | -9.9% | 0.57% | -44.6% |
| DCPH | DECIPHERA PHARMACEUTICALS INC | $36,291,000 | -7.2% | 1,068,000 | 0.0% | 0.57% | -16.2% | |
| AMRN | AMARIN CORP PLCsponsored adr | $30,600,000 | +16.4% | 6,000,000 | 0.0% | 0.48% | +5.3% | |
| PRAX | PRAXIS PRECISION MEDICINES INC | $29,584,000 | +1.1% | 1,600,000 | 0.0% | 0.46% | -8.6% | |
| SNDX | Sell | SYNDAX PHARMACEUTICALS INC | $29,525,000 | -42.7% | 1,545,000 | -48.5% | 0.46% | -48.2% |
| RNA | Buy | AVIDITY BIOSCIENCES INC | $28,325,000 | +110.3% | 1,150,000 | +111.0% | 0.44% | +90.2% |
| KYMR | New | KYMERA THERAPEUTICS INC | $26,771,000 | – | 455,750 | +100.0% | 0.42% | – |
| New | DICE THERAPEUTICS INC | $26,200,000 | – | 800,000 | +100.0% | 0.41% | – | |
| BIIB | New | BIOGEN INC | $23,771,000 | – | 84,000 | +100.0% | 0.37% | – |
| New | NUVALENT INC | $22,288,000 | – | 1,257,671 | +100.0% | 0.35% | – | |
| AVDL | Sell | AVADEL PHARMACEUTICALS PLCsponsored adr | $22,295,000 | -24.1% | 2,275,000 | -47.9% | 0.35% | -31.5% |
| DSGN | DESIGN THERAPEUTICS INC | $21,570,000 | -18.3% | 1,468,318 | 0.0% | 0.34% | -26.1% | |
| New | TANGO THERAPEUTICS INC | $20,042,000 | – | 1,550,000 | +100.0% | 0.32% | – | |
| FENC | FENNEC PHARMACEUTICALS INC | $15,731,000 | +29.2% | 1,670,000 | 0.0% | 0.25% | +16.5% | |
| ADVM | ADVERUM BIOTECHNOLOGIES INC | $15,082,000 | -38.0% | 6,950,000 | 0.0% | 0.24% | -44.0% | |
| MRUS | Sell | MERUS N V | $9,900,000 | -28.8% | 450,000 | -31.8% | 0.16% | -35.5% |
| GNCA | GENOCEA BIOSCIENCES INC | $9,762,000 | -17.9% | 5,084,184 | 0.0% | 0.15% | -26.1% | |
| SRPT | New | SAREPTA THERAPEUTICS INCcall | $2,194,000 | – | 200,000 | +100.0% | 0.03% | – |
| IOVA | New | IOVANCE BIOTHERAPEUTICS INCcall | $1,540,000 | – | 650,000 | +100.0% | 0.02% | – |
| APLS | Buy | APELLIS PHARMACEUTICALS INCcall | $1,260,000 | -62.5% | 1,515,000 | +531.2% | 0.02% | -65.5% |
| XLRN | New | ACCELERON PHARMA INCcall | $32,000 | – | 476,100 | +100.0% | 0.00% | – |
| ALNY | Exit | ALNYLAM PHARMACEUTICALS INCcall | $0 | – | -150,000 | -100.0% | -0.02% | – |
| ARPO | Exit | AERPIO PHARMACEUTICALS INC | $0 | – | -4,500,000 | -100.0% | -0.13% | – |
| ADAP | Exit | ADAPTIMMUNE THERAPEUTICS PLCsponsored adr | $0 | – | -2,024,400 | -100.0% | -0.15% | – |
| BCTG | Exit | BCTG ACQUISITION CORP | $0 | – | -800,000 | -100.0% | -0.16% | – |
| CNTA | Exit | CENTESSA PHARMACEUTICALS PLCsponsored ads | $0 | – | -500,000 | -100.0% | -0.19% | – |
| OLMA | Exit | OLEMA PHARMACEUTICALS INC | $0 | – | -876,986 | -100.0% | -0.43% | – |
| RLMD | Exit | RELMADA THERAPEUTICS INC | $0 | – | -935,000 | -100.0% | -0.52% | – |
| CNST | Exit | CONSTELLATION PHARMACEUTICALS INC | $0 | – | -3,210,000 | -100.0% | -1.89% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-11-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMICUS THERAPEUTICS INC | 36 | Q3 2023 | 17.9% |
| MIRATI THERAPEUTICS INC. | 35 | Q3 2023 | 17.2% |
| BIOMARIN PHARMACEUTICAL INC | 31 | Q3 2023 | 8.0% |
| SAREPTA THERAPUTICS INC | 28 | Q3 2023 | 14.8% |
| ASCENDIS PHARMA | 28 | Q3 2023 | 9.1% |
| ARGENX SE | 26 | Q3 2023 | 9.5% |
| IOVANCE BIOTHERAPEUTICS INC | 26 | Q3 2023 | 9.1% |
| FENNEC PHARMACEUTICALS INC | 25 | Q3 2023 | 0.4% |
| MADRIGAL PHARMACEUTICALS INC | 22 | Q3 2023 | 7.2% |
| XENON PHARMACEUTICALS INC | 22 | Q3 2023 | 3.3% |
View Avoro Capital Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Adverum Biotechnologies, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| DICE Therapeutics, Inc. | February 14, 2023 | 2,525,555 | 5.3% |
| IOVANCE BIOTHERAPEUTICS, INC. | February 14, 2023 | 7,020,000 | 4.4% |
| IVERIC bio, Inc. | February 14, 2023 | 6,750,000 | 5.0% |
| Kura Oncology, Inc. | February 14, 2023 | 3,105,000 | 4.5% |
| Aadi Bioscience, Inc. | September 26, 2022 | 2,849,402 | 11.7% |
| ARENA PHARMACEUTICALS INC | February 11, 2022 | 1,235,000 | 2.0% |
| AVADEL PHARMACEUTICALS PLC | February 11, 2022 | 1,670,000 | 2.9% |
| FENNEC PHARMACEUTICALS INC. | February 11, 2022 | 1,200,000 | 4.6% |
| POINT Biopharma Global Inc.Sold out | February 11, 2022 | 0 | 0.0% |
View Avoro Capital Advisors LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G/A | 2024-04-23 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Avoro Capital Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.